Discovery STAGE Agents*
Further along the path of precision medicine
Endocyte currently has a prostate-specific membrane antigen (PSMA) targeted drug, a therapeutic for inflammatory diseases, and a therapeutic for the treatment of polycystic kidney disease under development.
EC1669 is a new approach to inflammation therapy, targeting a highly potent anti-folate drug to activated macrophages expressing folate receptors.
EC0371 POLYCYSTIC KIDNEY DISEASE (PKD)
EC0371 is a folate-targeted, water-soluble form of rapamycin that is being developed to selectively inhibit mTOR activity in polycystic kidneys to reduce abnormal growth.
EC1788 is an investigational, proprietary, injectable Folate-targeted SMDC consisting of a potent DNA-reactive cytotoxic agent. Strong anti-tumor effect has been observed in animals safely treated with EC1788, including curative activity in models of triple negative breast cancer. Preclinical development of EC1788 is anticipated to start before the end of this year.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.